Elon Musk's Chicago Loop May Be Ambitious to a Fault
*By Britt Terrell*
Elon Musk is a man with ideas...a lot of them.
But Vanity Fair's Maya Kosoff wonders if his latest project may be more than he can handle.
The Tesla and SpaceX CEO won his bid to build a tunnel from downtown Chicago to O'Hare International Airport, partnering with Mayor Rahm Emanuel to modernize the city's struggling transportation system.
The task, though, may be particularly tricky.
"With public infrastructure, you have contracts with the government, and digging a tunnel underneath the city literally disrupts people's lives. I think it's more impactful so therefore it's kind of the most difficult (problem) to solve," Kosoff said.
The issues are only exacerbated by the fact that the airport link is far from Musk's only project. His SpaceX still aims to send humans to Mars by 2014, and Tesla is developing new cars and trucks, even as it continues to struggle with meeting production targets and burns through cash.
And in her article, ["Is Elon Musk Scamming Chicago?"](https://www.vanityfair.com/news/2018/06/is-elon-musk-scamming-chicago), Kosoff points out that the cost and the time it will take to construct the Chicago Express Loop may also be far higher than anticipated.
"It's supposed to cost a billion dollars," Kosoff said. "But look at the cost of other public infrastructure projects in the country. It cost a billion dollars to build less than a mile of the expanded Q train on \[New York City's\] Upper East Side."
Musk estimates the 18-mile track will take three years to complete and says his Boring Company - not taxpayers - will foot the bill.
For the full interview, [click here](https://cheddar.com/videos/elon-musks-next-big-endeavor).
The global chip shortage continues to weigh on the automotive industry. For example, Ford says it is suspending or cutting production at eight of its factories in North America through next week due to the shortage. Balu Balakrishnan, President and CEO of Power Integrations, joins Cheddar News' Closing Bell, where he elaborates on why the chip shortage has dragged into 2022.
Peloton has weathered a seemingly never-ending storm the past few months: PR blunders, sinking customer demand, and in recent weeks, reported cost-cutting and potential layoffs. Now, several companies are said to be in the mix as potential buyers: Amazon, Netflix, Disney, and Apple. How likely is it that one of these companies pursues a deal — and how likely is it that it will be Apple who buys Peloton? Dan Ives, Managing Director of Equity Research at Wedbush Securities, joins Closing Bell to discuss his thoughts about Apple pursuing a Peloton takeover,
Astra aborted the launch for NASA ELaNa 41 Mission out of Cape Canaveral on Monday due to what was described as a minor issue, but the company's stock fell nearly 14 percent following the news. Jim Cantrell, CEO and co-founder of Phantom Space, which builds and launches spacecraft of its own, joined Cheddar to discuss the scrubbed mission. “The last thing you want is for this to go wrong, you're better to err on the side of safety expectations,” Cantrell explained, noting that the mission delay was a normal event.
Dating app Bumble announced its first acquisition, expanding into Europe by picking up Fruitz, a French Platform. The Fruitz app allows its users to convey dating preferences through fruit metaphors.
Meat production giant Tyson Foods reported a beat on its Q1 earnings. In spite of obstacles posed by supply chain issues and inflation, the company exceeded expectations on earnings per share and revenue.
TC BioPharm, a biopharmaceutical company focused on developing cell therapy products targeting, went public on the Nasdaq in January. CEO Bryan Kobel joined Cheddar to talk about the company's IPO launch, its cancer-fighting therapeutics tech, and its potential for using its research to treat COVID-19. "The opportunity here for us is to really get safety data and covid and expand into other areas," Kobel said. "So from COVID, where we hope to treat patients, hopefully maybe the elderly population, populations that that really can't handle the antivirals because they're too hard in the system, well then we'll expand out into maybe severe influenza Ebola, other viral and viral infections where we think we can be helpful."
